Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ: MYGN )

10.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024
MYGN stock results show that Myriad Genetics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
Management will also participate in four upcoming investor healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
80% of people diagnosed with anxiety, depression report losing years or decades of time 
From Myriad Genetics, Inc.
Via GlobeNewswire
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Earnings Preview
Via Benzinga
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
From Myriad Genetics, Inc.
Via GlobeNewswire
Peeling Back The Layers: Exploring Myriad Genetics Through Analyst Insights
Via Benzinga
Evaluating Myriad Genetics: Insights From 4 Financial Analysts
Via Benzinga
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Management will also participate in two upcoming healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation
Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing. 
Via Benzinga
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
The Myriad Collaborative Research Registry has more than one million patient cases 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx... 
From Myriad Genetics, Inc.
Via GlobeNewswire
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. 
Via Benzinga
Myriad Genetics to Participate in Stephens Annual Investment Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.